Works matching IS 14440903 AND DT 2022 AND VI 52 AND IP 5

Results: 140

P100: CSL BEHRING CARES: SUPPORTING PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID) TO USE SUBCUTANEOUS IMMUNOGLOBULIN (HIZENTRA®) IN THE HOME.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 30, doi. 10.1111/imj.99_15894
Publication type:: Article

P99: ANTI‐SARS‐COV‐2 ANTIBODIES IN IMMUNOGLOBULIN PRODUCTS (COVIg).

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 30, doi. 10.1111/imj.98_15894
Publication type:: Article

P98: IMMUNODEFICIENT PAEDIATRIC PATIENTS TRANSITIONED TO SCIG BY TELEHEALTH DURING THE COVID19 PANDEMIC.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 30, doi. 10.1111/imj.97_15894
Publication type:: Article

P97: MEMORY RESPONSES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 VACCINATION IN PATIENTS WITH HYPER‐IMMUNOGLOBULIN E SYNDROMES.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 29, doi. 10.1111/imj.96_15894
Publication type:: Article

P96: NOT FOR PUBLICATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 29, doi. 10.1111/imj.95_15894
Publication type:: Article

P95: SEBETRALSTAT EFFECTIVENESS IN THE TREATMENT OF HEREDITARY ANGIOEDEMA ATTACKS RATED MILD OR MODERATE AT BASELINE IN THE PHASE 2 TRIAL.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 29, doi. 10.1111/imj.94_15894
Publication type:: Article

P94: THE IMPACT OF COVID‐19 ON PATIENTS WITH PRIMARY AND SECONDARY IMMUNODEFICIENCIES: A STUDY INTO THE PHYSIOLOGICAL, PSYCHOLOGICAL AND SOCIOLOGICAL EFFECTS.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 29, doi. 10.1111/imj.93_15894
Publication type:: Article

P93: REAL LIFE EXPERIENCE WITH OMALIZUMAB IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA (CSU) IN A METROPOLITAN SPECIALIST CLINIC.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 29, doi. 10.1111/imj.92_15894
Publication type:: Article

P92: THYMIC TRANSPLANTATION IN COMPLETE DIGEORGE SYNDROME COMPLICATED BY CYTOMEGALOVIRUS AND COVID‐19 INFECTION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 28, doi. 10.1111/imj.91_15894
Publication type:: Article

P91: MOVING BEYOND SIMPLE CLINICAL SEVERITY SCALES FOR HEREDITARY ANGIOEDEMA: DEVELOPMENT AND PILOT TESTING OF A MULTIFACTORIAL ASSESSMENT TOOL.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 28, doi. 10.1111/imj.90_15894
Publication type:: Article

P10: BASELINE DEMOGRAPHICS, COMORBIDITIES, AND TREATMENT PATTERNS IN ASIAN ADULTS WITH ATOPIC DERMATITIS WHO RECEIVED DUPILUMAB IN A REAL‐WORLD SETTING.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 7, doi. 10.1111/imj.9_15894
Publication type:: Article

P90: LANADELUMAB EFFICACY AND SAFETY REGARDLESS OF BASELINE ATTACK RATE IN PATIENTS WITH PREVIOUS LONG‐TERM PROPHYLAXIS OF HEREDITARY ANGIOEDEMA: A POST HOC SUBANALYSIS OF HELP OLE.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 27, doi. 10.1111/imj.89_15894
Publication type:: Article

P89: PATIENT PERCEPTIONS OF HEALTH‐RELATED QUALITY OF LIFE IN AN AUSTRALIAN ADULT PRIMARY IMMUNODEFICIENCY COHORT.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 27, doi. 10.1111/imj.88_15894
Publication type:: Article

P88: EVEN THE PROSTATE; A CASE OF UROLOGICAL IGG4‐RELATED DISEASE.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 27, doi. 10.1111/imj.87_15894
Publication type:: Article

P87: THE CHANGING LANDSCAPE OF HEREDITARY ANGIOEDEMA MANAGEMENT IN AUSTRALIA: A RETROSPECTIVE SINGLE CENTRE ANALYSIS.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 26, doi. 10.1111/imj.86_15894
Publication type:: Article

P86: VEXAS SYNDROME: A CASE OF TREATMENT REFRACTORY, SEVERE AUTOINFLAMMATORY DISEASE.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 26, doi. 10.1111/imj.85_15894
Publication type:: Article

P85: ANTI‐SARS‐COV‐2 HYPERIMMUNE GLOBULIN FROM CONVALESCENT PLASMA: ACTIVITY & POTENTIAL APPLICATIONS.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 25, doi. 10.1111/imj.84_15894
Publication type:: Article

P84: PREDOMINANTLY ANTIBODY DEFICIENCY AND ENHANCED PI3K SIGNALLING IN B CELLS OF A PATIENT WITH A HETEROZYGOUS MISSENSE VARIANT IN SYK.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 25, doi. 10.1111/imj.83_15894
Publication type:: Article

P83: COMBINED IMMUNODEFICIENCY AND IMPAIRED PI3K SIGNALING IN A PATIENT WITH BIALLELIC LCP2 VARIANTS.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 25, doi. 10.1111/imj.82_15894
Publication type:: Article

P82: A CASE SERIES OF X‐LINKED AGAMMAGLOBULINEMIA IN CANTERBURY, NEW ZEALAND.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 25, doi. 10.1111/imj.81_15894
Publication type:: Article

P81: MEASURING THE CLASSICAL COMPLEMENT PATHWAY ACTIVITY – A COMPARISON OF TWO METHODS.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 24, doi. 10.1111/imj.80_15894
Publication type:: Article

P9: BETA LACTAM ALLERGY HISTORIES ARE NOT ADEQUATE TO ALLOW DELABELLING OF FLINDERS MEDICAL CENTRE INPATIENTS.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 7, doi. 10.1111/imj.8_15894
Publication type:: Article

P80: INSIGHTS INTO SMOOTH MUSCLE ANTIBODY TESTING AND REPORTING.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 24, doi. 10.1111/imj.79_15894
Publication type:: Article

P79: NEONATAL VITAMIN D AND ASSOCIATIONS WITH LONGITUDINAL ECZEMA AND FOOD ALLERGY FROM EARLY LIFE TO 25 YEARS OF AGE.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 24, doi. 10.1111/imj.78_15894
Publication type:: Article

P78: AN AUDIT OF INDUCTION HONEY BEE VENOM IMMUNOTHERAPY AT THE FIONA STANLEY HOSPITAL (ADULT AND PAEDIATRIC) AND OUR EXPERIENCE WITH THE SUBSEQUENT USE OF OMALIZUMAB AS AN ADJUNCTIVE THERAPY.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 23, doi. 10.1111/imj.77_15894
Publication type:: Article

P77: GAPS IN PATIENT CARE AND FOLLOW UP IN ADULTS PRESENTING WITH ANAPHYLAXIS.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 23, doi. 10.1111/imj.76_15894
Publication type:: Article

P76: HOW THE PROFESSIONAL CERTIFICATE ALLERGY NURSING SHORT‐COURSE CHANGED PRACTICE OF ONE MATERNAL CHILD AND FAMILY HEALTH NURSE: PARENT SUPPORT FOR INFANT ALLERGIES.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 23, doi. 10.1111/imj.75_15894
Publication type:: Article

P75: HOW THE DIMENSIONS OF LEARNING FRAMEWORK INFORMS NURSES' PRACTICE AND PARENTS' LEARNING EXPERIENCES: THE POTENTIAL FOR COGNITIVE LEARNING PRINCIPLES IN ALLERGY PATIENT/FAMILY EDUCATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 22, doi. 10.1111/imj.74_15894
Publication type:: Article

P74: PRELIMINARY CLINICAL EXPERIENCE OF ASSESSMENT FOR HEREDITARY ALPHA‐TRYPASEMIA IN A COHORT FROM AN OUTPATIENT TERTIARY ANAPHYLAXIS CLINIC.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 22, doi. 10.1111/imj.73_15894
Publication type:: Article

P73: LONGITUDINAL ASTHMA PHENOTYPES FROM CHILDHOOD TO MIDDLE‐AGE: A POPULATION‐BASED COHORT STUDY.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 22, doi. 10.1111/imj.72_15894
Publication type:: Article

P72: NOT FOR PUBLICATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 22, doi. 10.1111/imj.71_15894
Publication type:: Article

P71: CONTEMPORARY TRENDS IN ANAPHYLAXIS IN WESTERN AUSTRALIA: A LINKED DATA STUDY.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 22, doi. 10.1111/imj.70_15894
Publication type:: Article

P8: PEGYLATED LIPOSOMAL MEDICATIONS ARE HIGHLY EFFECTIVE REAGENTS FOR THE DIAGNOSIS OF POLYETHYLENE GLYCOL ALLERGY.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 7, doi. 10.1111/imj.7_15894
Publication type:: Article

P70: NOT FOR PUBLICATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 22, doi. 10.1111/imj.69_15894
Publication type:: Article

P69: MULTIDISCIPLINARY CARE OF CHILDREN WITH EOSINOPHILIC OESOPHAGITIS: THE QUEENSLAND EXPERIENCE.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 21, doi. 10.1111/imj.68_15894
Publication type:: Article

P68: ANAPHYLAXIS DATA OF WESTERN AUSTRALIAN CHILDREN PRESENTING TO A TERTIARY EMERGENCY DEPARTMENT BEFORE AND IN THE BEGINNING OF THE COVID‐19 ERA: DO WE RUN THIS SAFELY?

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 21, doi. 10.1111/imj.67_15894
Publication type:: Article

P67: ULTRA‐RUSH BEE VENOM DESENSITISATION EXPERIENCE FROM AN IMMUNOLOGY CENTRE IN THE SOUTH ISLAND OF NEW ZEALAND.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 21, doi. 10.1111/imj.66_15894
Publication type:: Article

P66: NOT FOR PUBLICATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 21, doi. 10.1111/imj.65_15894
Publication type:: Article

P65: THE VIRTUAL IMMUNOLOGY CLINIC FOR GENERAL PRACTICE (VIC‐GP) – USING AUTOMATION TO ENABLE A NOVEL AND EFFICIENT WORKFLOW THAT DELIVERS TIMELY ACCESS TO SPECIALIST CARE WHILE UPSKILLING GENERAL PRACTITIONERS.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 20, doi. 10.1111/imj.64_15894
Publication type:: Article

P64: NOT FOR PUBLICATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 20, doi. 10.1111/imj.63_15894
Publication type:: Article

P63: NOT FOR PUBLICATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 20, doi. 10.1111/imj.62_15894
Publication type:: Article

P62: NOT FOR PUBLICATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 20, doi. 10.1111/imj.61_15894
Publication type:: Article

P61: NOT FOR PUBLICATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 20, doi. 10.1111/imj.60_15894
Publication type:: Article

P7: NOT FOR PUBLICATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 7, doi. 10.1111/imj.6_15894
Publication type:: Article

P60: COVID‐19 VACCINATION IN PATIENTS WITH SUSPECTED OR CONFIRMED POLYETHYLENE GLYCOL ALLERGY.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 20, doi. 10.1111/imj.59_15894
Publication type:: Article

P59: SUCCESS OF DUPILUMAB IN PATIENTS AGED 4 ‐ 16 YEARS IN A TERTIARY PAEDIATRIC HOSPITAL.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 19, doi. 10.1111/imj.58_15894
Publication type:: Article

P58: CLINICAL AND HISTOLOGICAL REMISSION OF EOSINOPHILIC OESOPHAGITIS IN TWO PAEDIATRIC PATIENTS AFTER COMMENCEMENT OF DUPILUMAB: TWO BIRDS WITH ONE STONE.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 19, doi. 10.1111/imj.57_15894
Publication type:: Article

P57: NOT FOR PUBLICATION.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 19, doi. 10.1111/imj.56_15894
Publication type:: Article

P56: COMMUNICATION OF SEVERE ALLERGY IS TIME CRITICAL TO FIRST RESPONDERS.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 19, doi. 10.1111/imj.55_15894
Publication type:: Article

P55: PATIENT SATISFACTION AND SENSORY ATTRIBUTES OF TWO COMBINATION NASAL SPRAYS (OLOPATADINE HYDROCHLORIDE/MOMETASONE FUROATE MONOHYDRATE AND AZELASTINE HYDROCHLORIDE/FLUTICASONE PROPIONATE) FOR TREATMENT OF ALLERGIC RHINITIS IN AUSTRALIA.

Published in:: Internal Medicine Journal, 2022, v. 52, n. 5, p. 18, doi. 10.1111/imj.54_15894
Publication type:: Article